Trial Profile
Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Canagliflozin/teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 13 Jun 2017 Results from phase 3 studies in Japanese patient with Type-2-diabetes-mellitus (MT-2412-J01, MT-2412-J02 and MT-2412-J03) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 05 Aug 2016 Status changed from active, no longer recruiting to completed.
- 15 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.